Mark Sarnak, an expert from Tufts University, discusses the intricate relationship between chronic kidney disease (CKD) and cardiovascular risks. He highlights the rising incidence of CKD driven by obesity and diabetes, and the significance of efficient screening. Sarnak delves into the latest guidelines for managing cardiovascular risk in CKD patients, including the use of innovative treatments like SGLT2 inhibitors. He also touches on the complexities of prescribing antiplatelet medications and the future of personalized medicine in cardiovascular care.

Mark Sarnak, Chief of Nephrology at Tufts School of Medicine, dives deep into the role of renin-angiotensin system blockade in advanced chronic kidney disease. He discusses the complexities and risks associated with using ACE inhibitors and ARBs, particularly hyperkalemia and acute kidney injury. Highlighting meta-analyses, he reveals significant reductions in kidney failure events with these treatments. The conversation also covers new insights into potassium management and the promising role of SGLT2 inhibitors, capturing the optimism in nephrology communities.